Multiple Myeloma

Joshua Richter, MD, hematologist/oncologist, multiple myeloma, John Theurer Cancer Center, discusses using the FDA-approved multiple myeloma drug pomalidomide to treat patients with sickle cell disease.

James R. Berenson, MD, discusses a phase I study presented at the 2013 ASH meeting that analyzed the use weekly carfilzomib for patients with R/R multiple myeloma.

An improved assay for assessing MRD status in patients with multiple myeloma is contributing to the momentum for using MRD as a surrogate endpoint for survival in clinical trials and as a tool with the potential to help guide therapy choices.

Joshua Richter, MD, hematologist/oncologist, multiple myeloma, John Theurer Cancer Center, discusses the administration of carfilzomib.

Pomalidomide (Pomalyst) rode impressive trial results to accelerated FDA approval this year, and Kenneth Anderson thinks it will prove a valuable new tool in the fight against multiple myeloma

Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, describes the design of a phase II trial looking at the single-agent activity of the proteasome inhibitor MLN9708 for the treatment of patients with multiple myeloma.

With the arrival and incorporation into clinical practice of immunomodulatory drugs (IMiDs) and proteasome inhibitor therapy, patients with multiple myeloma are achieving deep, durable responses and disease control, and are living longer.

The investigational cancer medications being developed by Stemline Therapeutics attack only a tiny percentage of all tumor cells. But those few cells-the stem cells that resist most treatment and drive tumor growth-may just be the most important ones.

The first-in-class targeted agent filanesib has demonstrated promising activity in patients with relapsed and refractory multiple myeloma.

The combination of continuous lenalidomide and low-dose dexamethasone extends PFS and trends toward improving OS compared with the standard MPT in patients with transplant-ineligible newly diagnosed multiple myeloma.

Intervention in early or "smoldering" myeloma with a three-drug regimen led to complete responses in a group of high-risk patients, suggesting a window of opportunity that may delay or prevent progression to a debilitating disease state.

A higher cumulative dose of bortezomib, including a longer duration of treatment and/or higher dose intensity, appears to improve OS in patients with previously untreated multiple myeloma.

Several protocols of novel immune and targeted agents show promise alone and in combination, including monoclonal antibodies, immune therapies, and newer proteasome inhibitors.

Multiple new proteasome inhibitors currently in clinical or preclinical development bode well for potential future therapies for multiple myeloma, both in frontline and relapsed or refractory settings.

Age is no longer a consideration when determining whether an older patient with blood cancer is a candidate for stem cell transplantation.

Access to Doxil has been inconsistent since mid-2011, when the drug's sole manufacturer announced a voluntary shutdown of production to address significant manufacturing and quality concerns.

Researchers highlighted the latest developments in the treatment of multiple myeloma at the 2013 ASCO Annual Meeting. Noteworthy abstracts included updated data on pomalidomide, as well as research involving the novel agents daratumumab and elotuzumab.

In an interview with OncologyLive, Brian G.M. Durie, MD, provided details about the Black Swan initiative and how he expects the project to develop.

Patients with previously treated multiple myeloma responded well to therapy with the monoclonal antibody elotuzumab in combination with lenalidomide and low-dose dexamethasone, with a high objective response rate and longer progression-free survival.

As one of the world's top multiple myeloma physicians and researchers, Brian G.M. Durie, MD, can boil his mission down to one simple goal: saving lives. But it was two people the doctor couldn't save who have most affected his path.

An investigational monoclonal antibody called daratumumab has received breakthrough therapy designation from the FDA for the treatment of patients with double refractory multiple myeloma.

There have been waves of advancements in the treatment of multiple myeloma and further exploration of existing regimens and research into novel therapeutics hold the promise of advances.

James R. Berenson, MD, Medical and Scientific Director, Institute for Myeloma & Bone Cancer Research, Chief Executive Officer, Oncotherapeutics, discusses the a study of carfilzomib as a replacement for bortezomib for multiple myeloma patients refractory to a bortezomib-containing combination regimen.

Working in the laboratory and the clinic, Shaji K. Kumar, MD, has made a discovery: that there aren't enough hours in a day.

Shaji K. Kumar, MD, is working to understand the genomic intricacies of multiple myeloma, particularly the role played by activity associated with the TP53 gene.